<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05012761</url>
  </required_header>
  <id_info>
    <org_study_id>SR419-104</org_study_id>
    <nct_id>NCT05012761</nct_id>
  </id_info>
  <brief_title>The Pharmacokinetics (PK), Safety, Tolerability of SR419 in Healthy Volunteers</brief_title>
  <official_title>A Phase I Bridging Study to Evaluate the PK, Safety and Tolerability of SR419 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai SIMRD Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai SIMR Biotechnology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled phase I PK bridging study to evaluate&#xD;
      the PK, safety and tolerability of SR419 in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a Phase I study to evaluate the PK, safety, and tolerability of SR419 in healthy&#xD;
      volunteers. The study will include 3 single-ascending-dose (SAD) cohorts and 2 multiple-dose&#xD;
      cohorts (Part A and part B respectively), a total of 5 cohorts, and each cohort includes 3&#xD;
      stages: screening and baseline, treatment and safety monitoring, and safety follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 24, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Up to Day 7</time_frame>
    <description>Peak plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>Up to Day 7</time_frame>
    <description>Time of peak plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>Up to Day 7</time_frame>
    <description>Area under the plasma concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F</measure>
    <time_frame>Up to Day 7</time_frame>
    <description>Apparent oral clearance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2</measure>
    <time_frame>Up to Day 7</time_frame>
    <description>Terminal half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rac</measure>
    <time_frame>Up to Day 7</time_frame>
    <description>Accumulation ratio</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The frequency and severity of AEs in healthy volunteers administrated with single and repeated oral doses of SR419 capsules</measure>
    <time_frame>Up to Day12(+7 days) for the safety follow up since Day1</time_frame>
    <description>AE: Adverse Event</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>SR419 capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascending single and multiple doses of SR419 orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ascending single and multiple doses of SR419 placebo orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SR419 capsules</intervention_name>
    <description>Ascending single and multiple doses of SR419 orally</description>
    <arm_group_label>SR419 capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Ascending single and multiple doses of placebo orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy males and females who are 18 to 45 years of age.&#xD;
&#xD;
          2. Based on medical history, physical examination, laboratory examination, chest X-ray,&#xD;
             abdominal B-ultrasound, vital signs and ECG, the investigator considered that the&#xD;
             results were normal or abnormal but no clinical significance.&#xD;
&#xD;
          3. Bodyweight of male &gt; 50 kg, Bodyweight of female &gt; 45 kg and body mass index (BMI)&#xD;
             between 18 and28 kg/m2&#xD;
&#xD;
          4. Male subjects must agree to use contraception methods.&#xD;
&#xD;
          5. Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant history of central nervous system (CNS) disease, such as&#xD;
             cognitive disorder and seizures. History of non-clinically significant mild anxiety&#xD;
             (related to social stressors) or situational sleep disturbance &gt; 6 months ago could be&#xD;
             enrolled under the discretion of the Investigators.&#xD;
&#xD;
          2. Known history of renal dysfunction or creatinine clearance &lt; 90 mL/min (calculated&#xD;
             using the Cockcroft-Gault formula) at Screening.&#xD;
&#xD;
          3. Current or chronic history of liver disease or known hepatic or biliary abnormalities.&#xD;
&#xD;
          4. History of regular alcohol consumption within 6 months of screening defined as: an&#xD;
             average weekly intake of &gt;21 units for males or &gt;14 units for females. One unit is&#xD;
             equivalent to 8 g of alcohol: a half-pint (~285 mL) of beer, 1 glass (125 mL) of wine&#xD;
             or 1 measure (25 mL) of spirits.&#xD;
&#xD;
          5. History of significant drug abuse within one year of screening or use of soft drugs&#xD;
             (such as marijuana) within 3 months prior to screening or hard drugs (such as cocaine,&#xD;
             methamphetamine, crack) within 1 year prior to screening.&#xD;
&#xD;
          6. History of sensitivity to any of the investigational medicinal products (IMPs), or&#xD;
             components thereof or a history of drug or other allergy that, in the opinion of the&#xD;
             Investigator or Medical Monitor, contraindicates participation.&#xD;
&#xD;
          7. History of asthma (excluding resolved childhood asthma), severe allergic responses.&#xD;
&#xD;
          8. History of hypercoagulable state or history of thrombosis.&#xD;
&#xD;
          9. A positive Hepatitis B surface antigen, positive Hepatitis C antibody and positive&#xD;
             test for human immunodeficiency virus (HIV) antibody.&#xD;
&#xD;
         10. within 6 months of screening, Smoking more than 4 cigarettes per day (including&#xD;
             e-cigarettes).&#xD;
&#xD;
         11. A positive drug/alcohol result at Screening or Day -1.&#xD;
&#xD;
         12. Donation or lost in excess of 500 mL of blood within 56 days of Day 1 or donation of&#xD;
             plasma within 14 days of Day 1.&#xD;
&#xD;
         13. The subject has participated in a clinical trial within 3 months of receiving IMP.&#xD;
&#xD;
         14. Use of medication other than topical products without significant systemic absorption.&#xD;
&#xD;
         15. Unable to refrain from consumption of Seville oranges, grapefruit or grapefruit juice&#xD;
             within 24h prior to the first dose of IMP until the Safety Follow-up visit.&#xD;
&#xD;
         16. Unable to refrain from consumption of alcohol, products containing caffeine or&#xD;
             xanthine (such as coffee, tea, cola, chocolate) within 7 days prior to the first dose&#xD;
             of IMP until the Safety Follow-up visit.&#xD;
&#xD;
         17. Breast-feeding and/or lactating subject.&#xD;
&#xD;
         18. Any reason which, in the opinion of the Investigator, would prevent the subject from&#xD;
             participating in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen Yu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Clinical Research Center Phase I Clinical Research Unit (SCRC-PCRU)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tina Zhao</last_name>
    <phone>+862161161537</phone>
    <email>contact@simrbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Clinical Research Center Phase I Clinical Research Unit (SCRC-PCRU)</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen Yu</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 17, 2021</study_first_submitted>
  <study_first_submitted_qc>August 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

